ACC.17 Stroke, Major Bleeding Risk Low with Dabigatran Etexilate Publish Date March 19, 2017 The data represents ~3,000 patients who had received the study drug in Phase 3 of GLORIA-AF with up to 2 years follow-up.
ACC.17 Anticoagulants Compared in A-fib Patients Undergoing Catheter Ablation Publish Date March 20, 2017 Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.